CO2019004756A2 - Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño - Google Patents
Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueñoInfo
- Publication number
- CO2019004756A2 CO2019004756A2 CONC2019/0004756A CO2019004756A CO2019004756A2 CO 2019004756 A2 CO2019004756 A2 CO 2019004756A2 CO 2019004756 A CO2019004756 A CO 2019004756A CO 2019004756 A2 CO2019004756 A2 CO 2019004756A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- disorders
- treatment
- procedure
- obtaining
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
RESUMEN La presente invención se relaciona con nuevos e inventivos compuestos derivados benzimidazólicos farmacológicamente activos, los cuales sorprendentemente poseen elevada afinidad a los receptores MT1 y MT2 de la melatonina y baja afinidad a las enzimas del complejo CYP450, especialmente a la CYP1A2. También se describen nuevas e inventivas rutas de síntesis de estos compuestos, composiciones farmacéuticas que comprenden los mismos y el uso de estos compuestos en el tratamiento de individuos acometidos por desórdenes psiquiátricos y/o trastornos del sueño relacionados con estos receptores (especialmente la depresión, la ansiedad y los trastornos del ciclo circadiano), además del procedimiento de producción de la composición.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR102016024814A BR102016024814A2 (pt) | 2016-10-24 | 2016-10-24 | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
PCT/BR2017/050320 WO2018076090A1 (en) | 2016-10-24 | 2017-10-23 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019004756A2 true CO2019004756A2 (es) | 2019-05-21 |
Family
ID=62023150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0004756A CO2019004756A2 (es) | 2016-10-24 | 2019-05-09 | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño |
Country Status (21)
Country | Link |
---|---|
US (2) | US10781182B2 (es) |
EP (2) | EP3529234B1 (es) |
JP (1) | JP7194683B2 (es) |
KR (1) | KR102594251B1 (es) |
CN (2) | CN115181108A (es) |
AR (1) | AR109467A1 (es) |
AU (1) | AU2017351756B2 (es) |
BR (2) | BR102016024814A2 (es) |
CA (1) | CA3042040A1 (es) |
CL (1) | CL2019001105A1 (es) |
CO (1) | CO2019004756A2 (es) |
DK (1) | DK3529234T3 (es) |
EC (1) | ECSP19032963A (es) |
ES (1) | ES2970546T3 (es) |
FI (1) | FI3529234T3 (es) |
MX (1) | MX2019004782A (es) |
PE (1) | PE20191046A1 (es) |
PT (1) | PT3529234T (es) |
SG (2) | SG11201903113TA (es) |
UY (1) | UY37334A (es) |
WO (1) | WO2018076090A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20220255T1 (hr) | 2016-10-24 | 2022-04-29 | Astrazeneca Ab | Derivati 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izokinolina koji su korisni u liječenju raka |
BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
LT3494116T (lt) | 2017-01-30 | 2020-01-10 | Astrazeneca Ab | Estrogeno receptorių moduliatoriai |
AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5260051A (en) | 1990-12-17 | 1993-11-09 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions comprising phosphate ester compounds containing a beneficial reagent component |
FR2674524B1 (fr) | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2680366B1 (fr) * | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
JP3559045B2 (ja) * | 1994-06-10 | 2004-08-25 | ナウチノ−イススレドバテルスキ インスティテュト ファルマコロギイ ロスシイスコイ アカデミイ メディツィンスキフ ナウク | 薬理学的活性を有する2−メルカプトベンズイミダゾール誘導体 |
US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
FR2738818B1 (fr) | 1995-09-18 | 1997-12-05 | Valentonine | Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament |
US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
JP2884153B2 (ja) * | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
NZ335910A (en) | 1996-12-10 | 2000-11-24 | Bristol Myers Squibb Co | Benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane melatonergic agents useful in treating sleep disorders and circadian rhthym related disorders |
US6214869B1 (en) | 1998-06-05 | 2001-04-10 | Bristol-Myers Squibb | Heterocyclic cis cyclopropane derivatives as melatonergic agents |
ATE257834T1 (de) | 1999-06-30 | 2004-01-15 | Bristol Myers Squibb Co | Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe |
WO2003062224A1 (en) * | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
US20070191447A1 (en) | 2004-02-23 | 2007-08-16 | Toru Kodo | Novel heterocyclic compound |
ES2264641B1 (es) * | 2005-06-17 | 2008-03-01 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios. |
US20090298811A1 (en) * | 2006-09-12 | 2009-12-03 | Pfizer Inc | Benzimidazolone derivatives |
EP2088861A4 (en) * | 2006-10-25 | 2010-07-07 | Takeda Pharmaceutical | BENZIMIDAZOLE COMPOUNDS |
RU2401831C2 (ru) * | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
-
2016
- 2016-10-24 BR BR102016024814A patent/BR102016024814A2/pt not_active Application Discontinuation
-
2017
- 2017-07-19 UY UY0001037334A patent/UY37334A/es unknown
- 2017-08-30 AR ARP170102402A patent/AR109467A1/es unknown
- 2017-10-23 KR KR1020197011842A patent/KR102594251B1/ko active IP Right Grant
- 2017-10-23 JP JP2019542758A patent/JP7194683B2/ja active Active
- 2017-10-23 US US16/344,721 patent/US10781182B2/en active Active
- 2017-10-23 CN CN202210815568.3A patent/CN115181108A/zh active Pending
- 2017-10-23 EP EP17865155.0A patent/EP3529234B1/en active Active
- 2017-10-23 PT PT178651550T patent/PT3529234T/pt unknown
- 2017-10-23 CA CA3042040A patent/CA3042040A1/en active Pending
- 2017-10-23 SG SG11201903113TA patent/SG11201903113TA/en unknown
- 2017-10-23 FI FIEP17865155.0T patent/FI3529234T3/fi active
- 2017-10-23 BR BR112019008197A patent/BR112019008197A2/pt active Search and Examination
- 2017-10-23 AU AU2017351756A patent/AU2017351756B2/en active Active
- 2017-10-23 MX MX2019004782A patent/MX2019004782A/es unknown
- 2017-10-23 ES ES17865155T patent/ES2970546T3/es active Active
- 2017-10-23 CN CN201780079647.XA patent/CN110088092B/zh active Active
- 2017-10-23 EP EP20185268.8A patent/EP3741760A1/en active Pending
- 2017-10-23 PE PE2019000861A patent/PE20191046A1/es unknown
- 2017-10-23 SG SG10202009001TA patent/SG10202009001TA/en unknown
- 2017-10-23 DK DK17865155.0T patent/DK3529234T3/da active
- 2017-10-23 WO PCT/BR2017/050320 patent/WO2018076090A1/en active Application Filing
-
2019
- 2019-04-23 CL CL2019001105A patent/CL2019001105A1/es unknown
- 2019-05-09 CO CONC2019/0004756A patent/CO2019004756A2/es unknown
- 2019-05-09 EC ECSENADI201932963A patent/ECSP19032963A/es unknown
-
2020
- 2020-05-13 US US15/930,990 patent/US11091445B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019004756A2 (es) | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño | |
CO2021005987A2 (es) | Compuestos de anillo fusionado | |
CL2020003425A1 (es) | Nuevos derivados heterocíclicos útiles como inhibidores de shp2 (divisional solicitud n° 201902698) | |
CL2019002103A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa. | |
CO2020004249A2 (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
DOP2011000076A (es) | Derivados de heteroaril amidas y su uso como activadores de glucoquinasa | |
EA200701588A1 (ru) | Способы получения замещённых фенилпиразолмочевин | |
PE20190181A1 (es) | Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas | |
UY37378A (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus | |
UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
CY1121898T1 (el) | Ενωσεις αμιδιου ως αγωνιστες tου υποδοχεα 5-ht4 | |
UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
CL2009000445A1 (es) | Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion. | |
EA201000675A1 (ru) | Производные хромана как модуляторы trpv3 | |
CL2018000856A1 (es) | Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida. | |
UY29631A1 (es) | Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica | |
EA201691252A1 (ru) | Соединения индазола в качестве агонистов 5-ht-рецептора | |
MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. | |
EA201990362A1 (ru) | Аналог вортиоксетина и его применение и получение | |
CY1110087T1 (el) | Μεθοδοι παρασκευης ενωσεων που περιεχουν πυρραζολιο | |
CL2012001601A1 (es) | Compuestos derivados de tiazoles biciclicos, composición farmacéutica; proceso para preparar la composición farmacéutica; kit farmacéutico que los comprende; y su uso en la prevención o tratamiento de enfermedades en las cuales el efecto neuromodulador de los moduladores alostericos de mglur5 es beneficioso. | |
BR112018071548A2 (pt) | compostos heterocíclicos bicíclicos substituídos | |
UY32447A (es) | Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia | |
UY32448A (es) | Derivados de 3-benzofuranil-indol-2-ona-3-acetamidopiperazinas sustituidos, su preparacion y su aplicacion en terapeutica |